Every intervention Outliyr has scored for traumatic brain injury, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for traumatic brain injury; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
29 of 75 evaluated interventions score 3.0+ out of 10 for traumatic brain injury · 5 comparisons
A cautious tbi score of 7.5/10 fits Neurofeedback, with Cortoos et al. 2010 preventing a stronger claim. TBI is a strong practical use case among clinicians and athletes, but the literature is…
Read the Neurofeedback report →BPC-157 tbi earns 7.0/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits tbi when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly…
Read the BPC-157 report →HRV Biofeedback has a 6.5/10 tbi case because Tan, Dao, Farmer, Sutherland, Gevirtz 2011 supports a plausible benefit. Systematic review of 7 studies; RCT data show improved executive function post-TBI in supervised…
Read the HRV Biofeedback report →A cautious tbi score of 6.5/10 fits Vagus Nerve Stimulation, with Badran et al. 2018 preventing a stronger claim. Post-concussion autonomic dysregulation is a good mechanistic fit; clinical evidence remains pilot-stage, so…
Read the Vagus Nerve Stimulation report →TB-500 (Thymosin Beta-4 Fragment) rates 6.5/10 for tbi; outcomes matter more than mechanism. TBI scoring is based on animal evidence, especially Xiong 2012 showing neuroprotective and neurorestorative effects after experimental traumatic brain…
Read the TB-500 (Thymosin Beta-4 Fragment) report →TBI evidence is mixed but meaningful for chronic persistent post-concussion protocols. Boussi-Gross 2013 reports cognitive and quality-of-life improvements after forty sessions. Hadanny 2018 supports a retrospective cohort. Wolf 2012 prevents a high…
Read the Hyperbaric Oxygen Therapy report →Zone 2 Cardio earns 5.0/10 for tbi because Lang 2024 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: Subsymptom aerobic exercise is used in…
Read the Zone 2 Cardio report →Glycine tbi earns 5.0/10 because Soh 2024 anchors the most relevant signal. Glycine fits tbi because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The…
Read the Glycine report →Traumatic brain injury data are rodent-only but consistent and reproducible. Tβ4 treatment improved sensorimotor and cognitive function and increased neurogenesis in rat controlled cortical impact even when treatment started 6 hours post-injury,…
Read the Thymosin Beta-4 (Tβ4) report →TBI stays 5.0/10 because Semaglutide has no TBI-specific clinical evidence in this report, even though GLP-1 neuroprotection is mechanistically interesting. Yao 2024 supports metabolic benefits, which may matter indirectly for brain recovery…
Read the Semaglutide report →No direct traumatic brain injury evidence was verified. Protein adequacy may support recovery nutrition, but EAA-specific claims are not established.
Read the Essential Amino Acids report →No direct TBI evidence. Vestibular and balance considerations may matter clinically, but TBI-specific benefit claims would be premature.
Read the Whole-Body Vibration report →TBI support is mechanistically interesting and community-reported, but there is no human TBI RCT. Treat Lion's Mane as experimental adjunctive support only.
Read the Lion’s Mane report →TBI relevance comes from overlapping neuroprotection, BDNF, and ischemia-stress mechanisms, not from a dedicated traumatic-brain-injury RCT.
Read the Semax report →No direct traumatic-brain-injury evidence. Do not borrow from unrelated mitochondrial or neuroplasticity interventions.
Read the Ca-AKG (Calcium Alpha-Ketoglutarate) report →Traumatic brain injury is one of Cerebrolysin's better-supported uses, with a small-to-medium recovery effect in moderate-to-severe injury, which is why it scores moderate-to-high rather than higher. The single-center CAPTAIN II trial in…
Read the Cerebrolysin report →INSUFFICIENT_EVIDENCE for traumatic brain injury recovery in humans, despite broad neuroinflammation and autophagy hypotheses.
Read the Rapamycin report →TBI remains low and exploratory. Zhang 2018 supports neuronal apoptosis protection after brain hemorrhage in rats, but traumatic-brain-injury outcomes in humans are untested.
Read the GHK-Cu report →No direct TBI evidence supports metformin as a brain-injury protocol. Any neuroprotection discussion remains diabetes-confounded or preclinical.
Read the Metformin report →DHA has a credible brain-repair rationale, but TBI clinical evidence is not yet practice-changing.
Read the Omega-3 report →Hypogonadism is common after traumatic brain injury, and replacement may help if true deficiency exists. TRT should be based on endocrine testing after TBI, not used as a generic brain-recovery protocol.
Read the TRT (Testosterone Replacement Therapy) report →A small military mild-TBI signal exists alongside the neuroprotective mechanism, but the human outcome base is thin and not replicated at scale.
Read the NAC (N-Acetylcysteine) report →Post-acute exercise can support cognition and mood after brain injury, but high-intensity intervals do not belong in acute TBI management and require clinical progression.
Read the Norwegian 4×4 report →Neuroprotective antioxidant data is mostly animal or mechanistic. No human TBI RCT base.
Read the Astaxanthin report →Post-TBI pituitary dysfunction can involve GH deficiency, but tesamorelin itself has not been tested as a TBI therapy. Endocrine evaluation matters more than unsupervised peptide use.
Read the Tesamorelin report →Preclinical traumatic brain injury models show mitochondrial stabilization and neuroprotection potential, but no human TBI trial was verified for SS-31.
Read the SS-31 (Elamipretide) report →Alternative brain fuel is a plausible mechanism after injury, but human exogenous-ketone TBI data is preclinical or absent.
Read the Exogenous Ketones report →Neurotrophic and synaptogenic mechanisms could matter after brain injury, but no direct TBI study exists for dihexa. This remains speculative despite the memory-model literature.
Read the Dihexa report →Nothing matches those filters.
Head-to-head reports and category rankings that name a winner on this use case.
Bromantane and semax tie at 7.1, and they are the only two in this category scored strong recommend. Selank is third at 6.9 if anxiety rather than focus…
Bromantane, for anything you plan to repeat. It scores 7.1 against phenylpiracetam's 5.5 and wins every shared use case that is not a floor tie: energy 6.2 to…
Cerebrolysin scores 6.3 and P-21 scores 5.0, and the gap is entirely about human data. Cerebrolysin has thousands of trial participants, contested by two independent Cochrane reviews. P-21…
Semax scores 7.1 and cerebrolysin 6.3. Semax wins cognition, neuroplasticity and nerve regeneration, costs an ESTIMATED $12 to $60 a month, and goes up your nose. Cerebrolysin wins…
Semax scores 7.1 against dihexa's 4.4, and that gap is real. Semax wins every cognitive use case we scored and carries human stroke data. Dihexa has zero human…
Neurofeedback, at 7.5 out of 10 for traumatic brain injury. A cautious tbi score of 7.5/10 fits Neurofeedback, with Cortoos et al.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 5.0 out of 10 for traumatic brain injury.
Dihexa scores 3.0 out of 10 for traumatic brain injury but only 4.4 overall, landing in the caution tier once safety, side effects, cost and effort are counted.
29 of the 75 interventions evaluated for traumatic brain injury score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
